Ternary nanocomposite carriers based on organic clay-lipid vesicles as an effective colon-targeted drug delivery system: preparation and in vitro/in vivo characterization by 泥쒖옱�씗
Kim et al. J Nanobiotechnol           (2020) 18:17  
https://doi.org/10.1186/s12951-020-0579-7
RESEARCH
Ternary nanocomposite carriers based 
on organic clay-lipid vesicles as an effective 
colon-targeted drug delivery system: 
preparation and in vitro/in vivo characterization
Hyeon Young Kim1†, Jae Hee Cheon2†, Sang Hoon Lee1, Jeong Youn Min1, Seung‑Yun Back1, Jae Geun Song1, 
Da Hye Kim2, Soo‑Jeong Lim3 and Hyo‑Kyung Han1*
Abstract 
This study aimed to develop a new colon‑targeted drug delivery system via the preparation of ternary nanocompos‑
ite carriers based on organic polymer, aminoclay and lipid vesicles. Budesonide (Bud), an anti‑inflammatory drug was 
chosen as a model drug and encapsulated into three different formulations: liposome (Bud‑Lip), aminoclay‑coated 
liposome (AC‑Bud‑Lip), and  Eudragit® S100‑aminoclay double coated liposome (EAC‑Bud‑Lip). The formation of the 
aminoclay‑lipid vesicle nanocomposite was confirmed by energy dispersive X‑ray spectrum, transmission electron 
microscopy, and Fourier‑transform infrared spectroscopy. All formulations were produced with a high encapsulation 
efficiency in a narrow size distribution. Drug release from EAC‑Bud‑Lip was approximately 10% for 2‑h incubation 
at pH 1.2, implying the minimal drug release in acidic gastric condition. At pH 7.4, EAC‑Bud‑Lip underwent signifi‑
cant size reduction and exhibited drug release profiles similar to that from AC‑Bud‑Lip, implying the pH‑dependent 
removal of the outer coating layer. Compared to free Bud solution, EAC‑Bud‑Lip achieved a higher drug uptake in 
Caco‑2 cells and exhibited a stronger inhibition of TNF‑α and IL‑6 secretion in LPS‑stimulated Raw264.7 cells. Fur‑
thermore, a bio‑distribution study in mice demonstrated that  Eudragit® S100‑aminoclay dual coating led to a higher 
colonic distribution with a longer residence time, which correlated well with the delayed systemic drug exposure in 
rats. Taken together, the present study suggests that the ternary nanocomposite carrier consisting of  Eudragit® S100, 
aminoclay, and lipid vesicle might be useful as an effective colon‑targeted drug delivery system.
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Background
Inflammatory bowel diseases (IBD) are chronic relapsing 
disorders of the gastrointestinal tract and are caused by 
complex interactions of environmental and genetic fac-
tors along with subsequent changes in immune dysregu-
lation [1, 2]. Ulcerative colitis and Crohn’s disease are two 
major types of IBD, where rectal bleeding, abdominal 
pain, diarrhea, and weight loss are frequent symptoms 
[1]. Current medical therapy for IBD attempts to sup-
press inflammatory episodes, and steroids are frequently 
prescribed due to their potent anti-inflammatory activity 
[1, 2]. However, the prolonged use of steroids often leads 
to toxic side effects associated with their systemic expo-
sure [2–4]. Therefore, targeted local drug delivery to the 
site of inflammation in the colon should be advantageous 
in avoiding the undesirable systemic toxicity of steroids 
and in lowering the dose.
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Nano-sized carriers have gained a great attention as 
a potential colon-specific drug delivery system due to 
their preferential uptake into inflamed colonic mucosa 
[5, 6]. Mucosal inflammation causes pathophysiologi-
cal changes such as disruption of the intestinal bar-
rier, increased mucus production, and the infiltration of 
immune-related cells, all of which provide an environ-
ment favorable for the accumulation of nanoparticles in 
inflamed regions [5, 6]. Therefore, nanoparticulate drug 
carriers have been extensively studied for targeting the 
inflamed intestinal mucosa.
Among nanocarriers, liposomes are promising deliv-
ery vectors since they are biocompatible, biodegrad-
able, and capable of encapsulating both hydrophilic and 
hydrophobic drugs [7, 8]. In addition, liposomes can 
undergo various surface modifications to control the site 
of drug release and uptake as well as physiological stabil-
ity [9–11]. For example, to enhance colonic drug delivery, 
the liposomal surface can be coated with mucoadhesive 
or pH-sensitive polymers to release the drug preferably 
at the distal part of the intestine and also lengthen the 
retention time in the colon [12–14]. Given that an ideal 
colon-specific delivery system should prevent prema-
ture drug release before reaching the colon, the proper-
ties of surface coating materials have a great impact on 
the effectiveness of liposomal drug carriers for colon 
targeting.
In the present study, bio-inorganic clay and pH-sensi-
tive polymers were selected as coating materials, and the 
ternary nanocomposite carrier was constructed based 
on organic polymer, aminoclay, and lipid vesicles. First, 
budesonide, an anti-inflammatory drug was selected as 
a model drug and encapsulated into anionic liposomes. 
Particularly, krill oil, which is rich in phospholipids dec-
orated with omega-3 polyunsaturated fatty acids, was 
added into this anionic liposome [15, 16]. Krill oil acts as 
a biocompatible and water dispersible surfactant, and it 
also possesses anti-inflammatory properties [17]. Then, 
the surface of these anionic liposomes was coated with 
aminoclay (3-aminopropyl functionalized magnesium 
phyllosilicate), a silicate-based material. Since aminoclay 
has a positive charge when dispersed in water, it can con-
struct a hybrid nanocomposite with anionic lipid vesicles 
via electrostatic interactions [18, 19]. Furthermore, ami-
noclay is biocompatible and may have anti-inflammatory 
effect [20, 21]. Therefore, lipid vesicles coated with amin-
oclay may be beneficial in improving the gastrointestinal 
(GI) stability of liposomes and may have the synergistic 
effect in anti-inflammation. Subsequently, the lipid ves-
icle-aminoclay nanocomposite underwent the surface 
coating with a pH-sensitive methacrylate copolymer 
 (Eudragit® S100). Since  Eudragit® S100 dissolves at pH 
greater than 7.0 [14, 22], a  Eudragit® S100 coating layer 
can be retained in the stomach and upper intestine but 
will dissolve in the distal intestine. This would allow for 
the targeted release of the drug in the distal intestine and 
colon. Such a drug delivery approach could be useful in 
lowering the therapeutic dose, reducing systemic side 
effects, and improving the physicochemical properties of 
drugs for oral delivery.
In the present study, three liposomal formulations of 
budesonide [uncoated liposome (Bud-Lip), aminoclay-
coated liposome (AC-Bud-Lip), and  Eudragit® S100/ami-
noclay-coated liposome (EAC-Bud-Lip)] were prepared 
by optimizing formulation variables. The in  vitro and 
in vivo effectiveness of these formulations was evaluated 
and compared with conventional powder formulations.
Results and discussion
Preparation and characterization of liposomes
As illustrated in Fig. 1, two oppositely charged polyelec-
trolytes, aminoclay and  Eudragit® S100, were assem-
bled directly on the liposomal surface via a layer by layer 
deposition to prepare pH-triggered drug releasing carri-
ers for colonic drug delivery. Each formulation was pre-
pared with narrow size distribution and high entrapment 
efficiency as summarized in Table  1. The net negative 
surface charge of Bud-Lip facilitated the alternate deposi-
tion of the positively charged aminoclay via electrostatic 
interaction. The addition of aminoclay resulted in a sur-
face charge reversal and an increase in the particle size 
from 117 to 194  nm. The addition of anionic  Eudragit® 
S100 as a pH-sensitive layer resulted in the alteration of 
the surface charge to negative and increased the particle 
size (321 nm) when compared to AC-Bud-Lip. This indi-
cated the successful fabrication of a pH-triggered drug-
releasing carrier, EAC-Bud-Lip (Table 1).
The formation of organic–inorganic nanocomposite 
carriers was also confirmed by multiple analysis includ-
ing TEM, EDX, and FT-IR analysis. As shown in Fig. 2a, 
TEM images showed the spherical shape of the liposomes 
and the coating layer surrounding the surface of the core 
liposome. Furthermore, the EDX spectrum of AC-Lip 
clearly indicated the distinct components originating 
from the phospholipids (P) and aminoclay (Si, Mg), which 
confirmed the integration of the lipid and aminoclay 
components within the electron dense hollow particles 
(Fig. 2b). EDX mapping and line scan analysis of AC-Bud-
Lip were also performed to examine the atomic distribu-
tion of Si, a distinct component of aminoclay. As shown 
in Fig.  2b, the Si component was distributed mainly in 
the shell surrounding the core liposome, confirming the 
surface coating with aminoclay. FT-IR analysis further 
supported the formation of organic–inorganic nanocom-
posite carriers. As shown in Fig.  2c. FT-IR spectrum of 
EAC-Bud-Lip indicated the characteristic absorption 
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bands of phospholipids, aminoclay and  Eudragit® S100, 
including a vibrational band of  PO2− at 1232  cm−1, a 
stretching vibration band of P=O at 1090 cm−1, a band 
of Si–O–Si at 1008  cm−1 from the phyllosilicate frame-
work of aminoclay, and bands from  Eudragit® S100, C=O 
at 1730  cm−1 and C–O stretch vibration at 1149  cm−1 
[23–25].
Collectively, the structural characterization confirmed 
the formation of a ternary nanocomposite carrier based 
on organic polymer, aminoclay, and lipid vesicles.
In vitro drug release study
Drug release study at different pHs
Drug release profiles from each liposomal formulation 
were examined at pH 1.2, 5.5, and 7.4 (Fig. 3a). Among 
the tested formulations, the delayed and reduced drug 
release was observed with EAC-Bud-Lip. Furthermore, 
EAC-Bud-Lip achieved more drug release as the sur-
rounding pH increased, displaying the pH-dependent 
drug release profiles. Particularly, EAC-Bud-Lip exhib-
ited minimal drug release (~ 10%) at pH 1.2 for 2  h, 
implying that it could prevent premature drug release 
in acidic gastric conditions. At pH 7.4, both EAC-Bud-
Lip and AC-Bud-Lip showed similar release profiles 
with approximately 55–60% of release in 24  h, since 
 Eudragit® S100 coating layer could be rapidly dissolved 
at pH 7.4 (Fig.  3a). This is also supported by the par-
ticle size change as illustrated in Fig.  3b. The overall 
particle size of Bud-Lip and AC-Bud-Lip was retained 
with minimal variation as the pH changed from acidic 
to neutral. In the case of EAC-Bud-Lip, its particle size 
was well maintained at pH 1.2 but rapidly decreased 
during the incubation at pH 7.4, implying the dissolu-
tion of the pH-sensitive  Eudragit® S100 coating layer at 
pH 7.4 (Fig. 3b).
To examine the structural and morphological changes 
of liposomal formulations during the drug release stud-
ies, TEM and FT-IR analysis were also conducted after 
2-h incubation in each release medium. As shown in 
Fig. 3c, TEM images showed that Bud-Lip and AC-Bud-
Lip underwent obvious shape change after 2-h incu-
bation at the acidic to neutral pH, along with greater 
change as pH increased. In the case of EAC-Bud-Lip, 
it maintained the spherical shape at pH 1.2 but dis-
played the morphological change at pH 5.5 and pH 7.4, 
particularly for the surface, which may lead to more 
drug leakage. In parallel, FT-IR spectra also indicated 
the structural change in coated liposomes (Fig.  3d). 
At all tested conditions, FT-IR spectra of AC-Bud-Lip 
appeared to be similar to those from Bud-Lip along 
with the disappearance of Si–O–Si band at 1008 cm−1, 
implying the removal of aminoclay coating layer during 
the incubation. In the case of EAC-Bud-Lip, the distinct 
absorption bands from aminoclay and  Eudragit® S100 
Fig. 1 Schematic illustration of organic clay‑lipid vesicles
Table 1 Characteristics of  liposomal formulations 
(Mean ± SD, n = 3)
Formulation Size 
(nm)
PDI Zeta 
potential 
(mV)
Encapsulation 
efficiency (%)
Bud‑Lip 117 ± 10 0.42 ± 0.02 − 21.4 ± 0.7 95.6 ± 1.7
AC‑Bud‑Lip 194 ± 12 0.25 ± 0.11 7.0 ± 2.9 74.7 ± 7.6
EAC‑Bud‑Lip 321 ± 18 0.40 ± 0.12 − 12.8 ± 5.8 82.7 ± 9.8
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Fig. 2 TEM images (a), TEM–EDX analysis data of AC‑Bud‑Lip (b), and FT‑IR spectra (c). EDX line scan analysis data were obtained along the arrow 
shown in b-1 
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were retained in the acidic conditions but disappeared 
at pH 7.4. This result supported the pH-dependent dis-
solution of outer coating layer of EAC-Bud-Lip.
Taken together, the results suggest that EAC-Bud-Lip 
may avoid premature drug release in acidic conditions 
and effectively retain the entrapped drug during their 
transit from the stomach until reaching the colon.
Fig. 3 In vitro drug release (a), size variation (b), TEM (c), and FT‑IR spectra (d) of liposomal formulations at the different pH (Mean ± SD, n = 3). TEM 
images and FT‑IR data were obtained at 2 h‑incubation in each drug release medium
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Drug release study in simulated gastrointestinal fluids
Since the bile salts and enzymes in the GI tract can accel-
erate the degradation of liposomal membrane leading to 
the drug leakage, the drug release profiles were examined 
in the presence of bile salts and/or digestive enzymes 
by using the simulated gastric  fluids (SGF) and intes-
tinal fluids  (SIF). As summarized in Fig.  4, the released 
drug amount was higher both in SGF and SIF compared 
to those incubated in buffers at the corresponding pH 
(Fig. 3a). In addition, drug release rate was enhanced in 
SIF relatively to SGF, which is also in agreement with the 
previous findings [26, 27]. These results may be because 
bile salts and the digestive enzyme (pancreatin) had syn-
ergistic effects on the destruction of liposomal mem-
branes in SIF. Particularly, bile salts could damage the 
liposomal integrity by solubilizing membrane and form-
ing transient pores, accelerating the drug leakage [28].
Collectively, the drug release study in SGF and SIF sug-
gest that EAC-Bud-Lip can prevent the premature drug 
release during passage through the stomach and release 
drugs rapidly in the intestinal environment at pH 7.4.
Cellular uptake study
While normal colonic pH ranges from 6.8 in the proxi-
mal colon to 7.2 in the distal colon, colonic pH values for 
IBD patients significantly vary from pH 5.5 to 2.3 [29, 30]. 
Therefore, in the present study, the cellular uptake of the 
developed formulations was assessed at pH 5.5 and pH 
7.4 in Caco-2 cells.
As shown in Fig.  5, all three liposomal formulations 
achieved approximatively twofold higher cellular uptake 
of budesonide than free drug solution at pH 7.4, implying 
that the liposomal vesicles effectively penetrated the cell 
membrane to deliver the drug. However, at pH 5.5, EAC-
Bud-Lip exhibited significantly lower cellular uptake 
than free drug solution while Bud-Lip and AC-Bud-Lip 
still retained their higher cellular uptake. These results 
could be explained by the pH-triggered dissolution of 
 Eudragit® S100 at pH 7.4. While the outer coating layer 
of  Eudragit® S100 was retained at pH 5.5, it was likely 
removed at pH 7.4. Several previous studies have also 
observed a rapid degradation of  Eudragit® S100 at pH 7.4 
[31, 32]. These results, in conjunction with the in  vitro 
stability data, suggest that EAC-Bud-Lip might mini-
mize drug absorption as well as premature drug release 
in upper GI tract. Once EAC-Bud-Lip reaches the lower 
intestine, it can be converted into AC-Bud-Lip, which 
provides a more favorable cellular uptake even at pH 5.5. 
Therefore, EAC-Bud-Lip may be able to improve drug 
delivery to the colon and confer effective cellular uptake 
in inflamed tissues exhibiting a low pH [33].
Bio-imaging assay by confocal microscopy also con-
firmed the effective intracellular distribution of fluo-
rescently labeled liposomes. As shown in Fig.  6, after 
incubation with each formulation at pH 7.4, strong 
fluorescence intensity of bodipy-tagged liposomes was 
observed in the cytoplasm of cells around DAPI-stained 
Fig. 4 In vitro drug release profiles of liposomal formulations 
in simulated gastric fluids (a) and simulated intestinal fluids (b) 
(Mean ± SD, n = 3)
Fig. 5 Cellular uptake of budesonide from liposomal formulations in 
Caco‑2 cells at pH 5.5 and pH 7.4 (Mean ± SD, n = 3). *p < 0.05
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nuclei. These results indicate the effective intracellular 
trafficking of the liposomal formulations. Considering 
that the particle size is a key parameter in determining 
the cellular uptake of nanoparticles, the obtained liposo-
mal formulations were in the size range that favors intes-
tinal uptake of the nanoparticles (100–200 nm) [34, 35].
Anti-inflammatory effect
In IBD, intestinal epithelial cells and macrophages secrete 
large amounts of chemokines and pro-inflammatory 
cytokines in the inflamed intestine [36]. Since IL-6, a 
versatile inflammatory cytokine, is involved in many 
physiological processes, especially acute and chronic 
inflammation, it has been used as a standard biomarker 
of inflammation in comparative studies [37]. TNF-α is 
also involved in inflammatory and immune responses 
regulation and it plays an important role in the pathogen-
esis of IBD [38].
Given that the production of pro-inflammatory 
cytokines such as TNF-α and IL-6 increase in colon 
epithelial cells and mucosa of IBD patients [37–39], the 
anti-inflammatory effects of the developed nanocarriers 
against the secretion of TNF-α and IL-6 were examined 
in LPS-stimulated RAW264.7 cells. None of the formula-
tions showed any toxicity to macrophages after 6 h-incu-
bation at the tested concentration (equivalent to 10 µM 
of budesonide).
As summarized in Fig.  7a, all formulations signifi-
cantly reduced LPS-induced production of TNF-α and 
IL-6. Interestingly, all liposomal formulations enhanced 
the anti-inflammatory effect of budesonide compared 
to free drug solution, which may be explained, in part, 
by the higher cellular uptake of drugs via nanocarri-
ers. Similar levels of inhibition between AC-Bud-Lip 
and EAC-Bud-Lip could result from the removal of the 
outer coating layer of EAC-Bud-Lip at pH 7.4. Further-
more, coated liposomes, such as AC-Bud-Lip and EAC-
Bud-Lip, exhibited higher inhibition effect than uncoated 
liposomes, implying that the surface coating with ami-
noclay may enhance the anti-inflammatory effect of 
Fig. 6 CLSM images showing the intracellular trafficking of bodipy‑tagged fluorescent liposomal vesicles in Caco‑2 cells. The first panel shows 
DAPI‑stained nuclei, and the second panel displays the green fluorescence related to bodipy. Scale bar is 20 μm
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nanocarriers. Therefore, we also tested the inhibition 
effect of empty carriers on the secretion of TNF-α and 
IL-6 under the same conditions. As shown in Fig.  7b, 
empty liposomes without surface coating exhibited an 
anti-inflammatory effect, which is consistent with previ-
ous studies that have observed the immunomodulatory 
ability of lipid-based nanoparticles [40, 41]. Moreover, 
the aminoclay-coating further enhanced the anti-inflam-
matory effect of lipid vesicles. These results suggest that 
surface coating of lipid vesicles with aminoclay may 
have a synergistic effect in the anti-inflammatory activ-
ity of lipid-based formulations. Consequently, the great-
est inhibition effect of coated liposomes on the secretion 
of TNF-α and IL-6 might be derived from the enhanced 
cellular uptake of drugs as well as the anti-inflammatory 
effect of aminoclay-lipid based composite nanocarriers.
Ex vivo imaging study
To evaluate the colon-targeted drug delivery potential 
of the developed nanocarriers, the gastrointestinal dis-
tribution of DiR-loaded formulations was examined in 
mice. After oral administration of each formulation to 
mice, whole gastrointestinal (GI) tract was removed at 6, 
12 and 24 h and the distribution of fluorescent dye was 
examined by using an in  vivo imaging system as shown 
in Fig. 8.
Blank liposomes were also administered in mice to dis-
criminate the effect of carrier material and no fluores-
cence signals were observed (Fig. 8). Uncoated liposomes 
showed low fluorescence signals in GI tracts, probably 
due to systemic absorption during the transition along 
the GI tract before reaching the colon (Fig.  8). Particu-
larly, no fluorescence signals were observed in colons at 
24 h post-dose of uncoated liposomes. In contrast, at 6 h 
post-dose, AC-Bud-Lip exhibited strong fluorescence 
signals mainly in the lower intestine and colon but the 
Fig. 7 Anti‑inflammatory effect of drug‑loaded formulations (a) and empty vehicles (b) in LPS‑stimulated Raw264.7 cells (Mean ± SD, n = 6). 
*p < 0.05
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fluorescence intensity gradually decreased with time, 
leading to the absence of fluorescence signals in the lower 
intestine and colon, which may be due to the colonic 
absorption or clearance via feces. Among the tested for-
mulations, dual-coated EAC-Bud-Lip exhibited domi-
nant fluorescence signals in the GI tract at all time points, 
implying that EAC-Bud-Lip may prevent premature drug 
release and subsequent systemic drug absorption in the 
upper intestine. Accordingly, compared to other formula-
tions, EAC-Bud-Lip achieved a much greater colonic dis-
tribution of fluorescence dye and retained fluorescence 
signals even after 24  h post-dose (Fig.  8). These results 
suggest that EAC-Bud-Lip should be more effective in 
enhancing drug delivery to the colon with longer resi-
dence time.
Pharmacokinetic study
To assess the effectiveness of the developed formulations 
as local drug delivery systems to reduce systemic effects, 
budesonide was replaced in each liposomal formulation 
by coumarin 6 (C6) to facilitate in  vivo detection and 
quantification in the colon after oral administration. Fol-
lowing oral administration of C6 solution or C6-loaded 
liposomal formulations, systemic exposure and colonic 
accumulation of C6 was determined in rats.
As summarized in Table 2 and Fig. 9, C6 solution and 
uncoated liposomes (C6-Lip) exhibited rapid absorption 
with  Tmax values of 1.6–2.0 h after oral administration in 
rats. In contrast, coated liposomes tended to have longer 
 Tmax and lower  Cmax, implying delayed absorption. Par-
ticularly, dual coated liposomes (EAC-C6-Lip) exhib-
ited prolonged drug exposure up to 24  h and  Cmax was 
Fig. 8 Ex‑vivo fluorescence images of the gastrointestinal tract of mice after oral administration of DiR‑labeled liposomal formulations
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reduced by about 35% compared to C6 solution (Table 2), 
implying that dual coated liposomes may be beneficial in 
reducing the toxicity associated with unnecessarily high 
 Cmax. In parallel, the colonic tissue distribution of C6 
was also evaluated after 24  h following the oral admin-
istration of each formulation in rats. As illustrated in 
Fig. 10a, confocal images revealed that EAC-C6-Lip was 
spread along the colon tissue, while C6 solution displayed 
negligible fluorescence intensity. In addition, quantita-
tive fluorescence analysis indicated that EAC-C6-Lip 
achieved much higher C6 concentrations in colonic tis-
sues than C6 solution, implying more favorable colonic 
drug delivery (Fig.  10b). Taken together, the observa-
tions from the pharmacokinetic study and colonic tissue 
accumulation study were consistent with gastrointestinal 
distribution study described above, which strongly sug-
gest more effective colonic drug delivery with longer resi-
dence time via double coated liposomes with aminoclay 
and  Eudragit® S100.  
Given that cationic nanoparticles adhere to the 
mucosal surface via the interaction between the posi-
tively charged nanoparticle and the negatively charged 
intestinal mucosa, the mucoadhesion properties of cati-
onic nanoparticles can promote better contact with the 
mucosal surface for cellular uptake and increase drug 
residence time in the GI tract. Therefore, shielding the 
cationic surface charge of nanocarriers before reach-
ing the colon and subsequent de-shielding in the colon 
should be advantageous for prolonged colonic drug deliv-
ery. In that sense, a  Eudragit® S100 coating layer should 
be beneficial in preventing premature drug release and 
undesired mucoadhesion of nanocarriers in the upper 
GI tract. Once it reaches the distal part of the intestine, 
the pH-dependent dissolution of  Eudragit® S100 releases 
positively charged AC-Bud-Lip which could interact with 
negatively charged colonic mucin and reduce the clear-
ance of nanocarriers, leading to longer residence time.
Taken together, pharmacokinetic studies in rats suggest 
that dual coated liposomal formulations with  Eudragit® 
S100 and aminoclay could be beneficial in increasing 
local drug delivery to the colon.
Conclusion
In the present study, three different liposomal formula-
tions were prepared with narrow size distribution and 
high encapsulation efficiency. Among the developed 
formulations, EAC-Bud-Lip showed good stability with 
minimal drug leakage in the acidic conditions and pH-
dependent dissolution of coated layer. Furthermore, 
EAC-Bud-Lip appeared to be effective at enhancing 
the cellular uptake and the anti-inflammatory effects of 
budesonide. In bio-distribution and pharmacokinetic 
studies, EAC-Bud-Lip exhibited higher colonic distribu-
tion with a longer residence time as well as lower  Cmax. 
These results suggest that EAC-Bud-Lip could be a prom-
ising colon-targeted delivery system.
Methods
Materials
Budesonide was obtained from Tokyo Chemi-
cal Industry Co., LTD. (Tokyo, Japan). 1,2-dimyris-
toyl-sn-glycero-3-phosphocholine (DMPC), 
1,2-dimyristoyl-sn-glycero-3-phospho-1′-rac-glycerol 
sodium salt (DMPG), and bodipy-cholesterol were pur-
chased from Avanti Polar Lipids, Inc. (Alabaster, AL, USA). 
d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS), 
cholesterol, lipopolysaccharides (LPS), 3-(4,5-dimethylth-
iazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), cou-
marin 6, pepsin, pancreatin, bile salt, and a BCA assay kit 
were obtained from Sigma Co. (St Louis, MO, USA). DiR 
(1,1′-dioctadecyl-3,3,3′,3′-tetramethylindotricarbocyanine 
iodide) was purchased from Invitrogen Molecular Probes 
(Karlsruhe, Germany).  Eudragit® S100 was donated by 
Evonik Korea Ltd. (Seoul, Korea). Dulbecco’s Modified 
Eagle’s medium (DMEM), Hank’s balanced salt solution 
(HBSS), non-essential amino acids, fetal bovine serum 
(FBS), penicillin–streptomycin, and all other reagents used 
Table 2 Pharmacokinetic parameters of  coumarin 6 
(C6) after  oral administration of  C6 in  the  different 
formulations to rats (Mean ± SD, n = 4)
Parameters Control (C6 
solution)
C6-Lip AC-C6-Lip EAC-C6-Lip
Cmax (ng/mL) 11.3 ± 1.46 10.1 ± 2.08 8.0 ± 4.3 7.4 ± 1.3
Tmax (h) 2.0 1.6 ± 0.5 4.0 ± 2.3 7.8 ± 10.9
AUC (ng h/
mL)
91.8 ± 21.0 97.0 ± 18.9 99.7 ± 38.4 99.9 ± 17.7
Fig. 9 Plasma concentration–time profiles after oral administration of 
coumarin 6 (C6) in different formulations in rats (Mean ± SD, n = 4)
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in cell culture studies were obtained from GE Healthcare 
Life Sciences (South Logan, UT, USA). All other chemicals 
and reagents were HPLC-grade.
Caco-2 cells and RAW264.7 cells were purchased from 
the Korean Cell Line Bank (Seoul, Korea). Cells were 
grown in DMEM containing 10% FBS, 1% non-essential 
amino acids, and 1% antibiotics and incubated at 37 °C in 
an atmosphere of 5%  CO2 and 90% relative humidity.
Preparation of liposomes
Budesonide loaded-liposomes (Bud-Lip) were prepared 
by the thin film method. Briefly, DMPC, DMPG, Krill oil, 
TPGS, cholesterol, and drug (14:7:3:11:5:1, mole ratios) 
were dissolved in chloroform. For DiR-loaded liposomes, 
0.5% DiR was included in the lipid mixture. After the 
lipids and the drug are thoroughly mixed in organic sol-
vent, the solvent was removed by rotary evaporation 
above 25  °C and the resultant lipid film was dried over-
night in a vacuum oven to remove the residual organic 
solvent. The resulting thin film was hydrated with 0.9% 
NaCl while stirring for 1 h. The mixture was, then, soni-
cated for 10 min. Finally, the liposome suspension was fil-
tered through a membrane (0.8-μm pore size) to remove 
the free (unencapsulated) drug.
Aminoclay coated-liposomes (AC-Bud-Lip) were pre-
pared via the electrostatic interactions between the 
positively charged aminoclay and the anionic surfaces of 
Bud-Lip. An aqueous solution of aminoclay (8  mg/mL) 
Fig. 10 In vivo localization of coumarin 6 (C6) in colons after oral administration of C6‑loaded liposomal formulations in rats. a Confocal images of 
C6‑loaded liposomes (EAC‑C6‑Lip) in colon cross sections prepared at 24 h (scale bar is 100 μm), b quantitation of C6 in colon tissues at 24 h after 
oral administration of each formulation (Mean ± SD, n = 3). *p < 0.05
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was mixed with an equal volume of Bud-Lip suspension 
(3  mg/mL) by stirring at 4  °C for 30  min. The resulting 
suspension was centrifuged through a membrane filter 
(MWCO = 30 kDa) at 15,000×g for 10 min at 4  °C. The 
pellets were re-suspended in 0.9% NaCl.
For  Eudragit® S100 coating, AC-Bud-Lip (3.5 mg/mL) 
was added drop-wise to an equal volume of  Eudragit® 
S100 (0.1% in 50  mM NaOH, pH 7.4) while stirring at 
4  °C for 30  min. The resulting suspension was centri-
fuged through a membrane filter (MWCO = 30  kDa) 
at 15,000×g for 10 min at 4  °C. The pellets were re-sus-
pended in 0.9% NaCl.
For the in vivo pharmacokinetic study in rats, budeso-
nide was replaced by the hydrophobic fluorescent marker 
C-6 using the same procedures described above.
Characterization of liposomes
The particle size and zeta potential of all liposomal for-
mulations were measured by Dynamic Light Scattering 
using a Zetasizer (Nano-ZS90, Malvern Instruments, Mal-
vern, UK). The polydispersity index (PDI) was also meas-
ured as a dimensionless number, which indicated the size 
distribution.
The encapsulation efficiency (EE %) of each formula-
tion was calculated using the following equation: EE 
(%) = the entrapped drug amount in liposomes/the total 
drug amount initially added × 100. The drug amount was 
measured by high-performance liquid chromatography 
(HPLC).
The morphology of each formulation was examined 
by transmission electron microscopy (TEM). Liposomal 
samples were stained with 2% phosphotungstic acid and 
air-dried. Samples were monitored by TEM. Composi-
tional elements of the developed formulations were also 
examined by using a TEM equipped with an Energy dis-
persive X-ray spectrometer (EDX).
Structural characterization of the liposomal formula-
tions was also performed using Fourier transform infra-
red spectroscopy (FT-IR) (Nicolet™ iS™ 5; Thermo Fisher 
Scientific) with a ZnSe crystal accessory. FT-IR spectra 
of all samples were obtained over a wavenumber range of 
4000–500 cm−1 with 64 scans at a resolution of 4 cm−1.
In vitro drug release study
Drug release at different pHs
The in  vitro drug release of liposomal formulations 
was evaluated at pH 1.2, 5.5, and 7.4. Each liposomal 
suspension (5  mL, equivalent to 3  μg/mL of budeson-
ide) was added to a Spectra/Por (Spectrum Labs, CA, 
USA) dialysis bag (MWCO = 12–14  kDa), which was 
immersed in 20  mL of release medium containing 1% 
Tween 80 at 37  °C with horizontal shaking (100  rpm). 
At predetermined time points, 1 mL of each sample was 
collected and replenished by an equal volume of fresh 
medium. Samples were analyzed by HPLC to determine 
the released drug amount from each formulation.
Variation in the size of liposomal formulations was 
also evaluated during the incubation at the different pHs. 
Each formulation was suspended in buffer solutions (pH 
1.2, pH 5.5, or pH 7.4) and incubated at 37 °C in a shaking 
water bath. At the predetermined time points, the sample 
was collected, and the particle size was measured. TEM 
and FT-IR analysis were also conducted to examine the 
structural and morphological changes during the incuba-
tion in each drug release medium.
Drug release in simulated gastrointestinal fluids
The in vitro drug release studies were carried out in the 
simulated gastric fluids (SGF) and intestinal fluids (SIF). 
SGF and SIF were prepared as described in the previ-
ous reports [26, 27] with slight modification, where SGF 
included pepsin (0.32 mg/mL) and SIF contained bile salt 
(0.5  mg/mL) and pancreatin (1  mg/mL). Each formula-
tion dispersed in SGF or SIF (5 mL, equivalent to 3 μg/mL 
of budesonide) was placed into a Spectra/Por (Spectrum 
Labs, CA, USA) dialysis bag (MWCO = 12–14  kDa), 
which was immersed in 20  mL of release medium con-
taining 1% Tween 80 at 37  °C with horizontal shaking 
(100 rpm). At predetermined time points, 1 mL of each 
sample was collected and replenished by an equal vol-
ume of fresh medium. Samples were analyzed by HPLC 
to determine the released drug amount from each 
formulation.
Cellular uptake study
Caco-2 cells were seeded in 6-well plates at a density of 
5 × 105 cells/well. After 5-days post-seeding, the medium 
was removed, and the cells were washed twice with PBS. 
Cells were then incubated with each formulation (Bud 
solution, Bud-Lip, AC-Bud-Lip, and EAC-Bud-Lip) at 
the concentration equivalent of 15 μM Bud. The uptake 
studies were performed at pH 5.5 and pH 7.4. After 6 h 
of incubation, the drug solutions were removed and the 
cells were washed three times using ice-cold PBS. After 
cell lysis, acetonitrile was added to the cell lysates with 
vigorous stirring followed by centrifugation at 15,000×g 
for 15 min. The supernatants were collected and the drug 
concentration was determined by HPLC. Protein quanti-
fication for each sample was performed using a BCA pro-
tein assay kit.
Confocal laser scanning microscopy (CLSM)
The intracellular localization of fluorescence-labeled 
liposomes was examined by confocal microscopy. Briefly, 
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cells were seeded onto culture slides at a density of 
1 × 105 cells/well and incubated for 24  h. After remov-
ing the medium, 1 μM of bodipy-tagged liposomes were 
added, and the cells were incubated for 6  h. At the end 
of incubation, the cells were fixed with 4% paraformalde-
hyde in PBS for 15  min at 4  °C and then washed three 
times with PBS. Fixed cells were incubated with blocking 
buffer (1% horse serum and 0.1% Triton X-100 in PBS) 
for 30  min at 4  °C, and their nuclei were stained with 
DAPI for 1  h at 4  °C. Images of the intracellular distri-
bution of liposomes were obtained by Nikon C1 confocal 
microscope and processed with EZ-C1 software (Nikon, 
Tokyo, Japan).
Assessment of anti-inflammatory activity
The suppression effect of liposomal formulations on 
the production of proinflammatory cytokines (IL-6 and 
TNF-α) was evaluated and compared with free drug 
solution. Raw264.7 macrophages were seeded in 96-well 
plates at a density of 5 × 104 cells/well. After incubation 
for 24  h, cells were treated with each formulation (free 
drug solution, Bud-Lip, AC-Bud-Lip and EAC-Bud-
Lip) at a concentration equivalent to 10 μM Bud for 3 h 
and then stimulated with LPS (0.1  μg/mL) for 3  h. At 
the end of incubation, the extracellular media was col-
lected. The amounts of TNF-α and IL-6 in each sample 
were determined by using their respective enzyme-linked 
immunosorbent assay (ELISA) kits (Thermo Fisher Sci-
entific, Waltham, MA) according to the manufacturer’s 
instructions.
The cytotoxicity of each formulation on macrophages 
was also assessed by using an MTT assay. Raw264.7 
macrophages were seeded in a 96-well plate and after 
24 h-incubation, cells were treated with each formulation 
at various concentrations for 4 h. At the end of incuba-
tion, 50 μL of MTT was added into each well and incu-
bated for another 4  h. Subsequently, the medium was 
removed and 100 μL of DMSO was added to dissolve the 
formazan crystals. The absorbance of each sample was 
determined by a microplate reader at 550 nm.
Ex-vivo imaging study
The gastrointestinal distribution of three different formu-
lations was evaluated in mice by using an in vivo imag-
ing system (IVIS) (FOBI; Neoscience, Suwon, Republic of 
Korea). The near-infrared dye DiR was loaded as a fluo-
rescent probe into each liposomal formulation.
Animal studies were carried out following the study 
protocol approved by the review committee of Dongguk 
University (IACUC-2017-016-1). Male C57BL/6 mice 
(8  weeks of age, body weight 23–28  g) were purchased 
from Orient Bio Inc. (Seongnam, Korea). All animals 
were allowed free access to water and were fasted for 24 h 
prior to the experiment. On the day of the experiment, 
DiR-loaded liposomes were administered orally to mice 
at a dose equivalent to 50 μg/kg of DiR. Blank liposomes 
(without DiR) were also tested. At predetermined time 
points (6, 12 and 24  h), the whole gastrointestinal tract 
of each mouse was isolated and the fluorescence sig-
nals were assessed by Spectral Lago X system (Spectral 
Instruments Imaging; Tucson, AZ, USA). Fluorescence 
images were obtained using an ICG filter at the excita-
tion and emission wavelengths of 745  nm and 800  nm, 
respectively.
Pharmacokinetic study
This animal study was carried out following the protocol 
approved by the review committee of Dongguk Univer-
sity (IACUC-2017-016-3). Male Sprague Dawley rats of 
220–250  g were purchased from Samtako Bio Co., Ltd 
(Osan, Korea). All rats were given free access to tap water 
and a normal standard chow diet (Superfeed Co., Wonju, 
Korea). Rats were fasted for 18 h before the experiments. 
On the day of the experiment, the rats were divided into 
four groups and administered each C6-loaded formula-
tion or free C6 solution (0.2 mg/kg) via oral gavage. Blood 
samples were collected at predetermined time points (0, 
0.5, 1, 2, 4, 6, 8, and 24 h) and centrifuged immediately 
at 13,000×g for 5  min. The obtained plasma samples 
were stored at − 80  °C until analyzed. Colons were also 
resected at 24 h post-dose, and rinsed with cold saline to 
remove the luminal content. The colon samples under-
went confocal microscopic examination and C6 content 
was quantified. The C-6 contents in the plasma and colon 
samples were extracted with a chloroform/methanol (1:1 
v/v) mixture and quantified with a fluorescence plate 
reader (SpectraMax M2, Molecular Devices, LCC., San 
Jose, CA).
HPLC analysis
Drug concentrations were determined by HPLC. The 
HPLC system (Flexar; Perkin Elmer, Waltham, MA, USA) 
consisted of an automatic injector, a UV detector and 
two solvent delivery pumps. Samples were injected into 
the HPLC system connected to a column (Gemini C18, 
4.6 × 150 mm, 5 μm; Phenomenex, Torrance, CA, USA). 
Chromatographic separation was achieved by eluting a 
mobile phase (methanol: 0.1% acetic acid = 73:27, v/ v) at 
a flow rate of 1  mL/min. The detection wavelength was 
set at 245 nm. The calibration curve was obtained in the 
range of 125–5000 ng/mL with good linearity  (R2 > 0.998).
Pharmacokinetic analysis and statistical analysis
Noncompartmental analysis was performed and the area 
under the plasma concentration–time curve (AUC) was 
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calculated using the linear trapezoidal method. The peak 
plasma concentration  (Cmax) and the time of reaching the 
peak plasma concentration  (Tmax) were observed from 
the experimental data.
All data are expressed as mean ± standard deviation 
(SD). Statistical analyses were performed using one-way 
ANOVA followed by Dunnett’s test. Values of p < 0.05 
were considered statistically significant.
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